Correct Answer: A. Amlodipine
In a patient with renal insufficiency presenting with oliguria (very low urine output), pedal edema, and hypertension, the choice of antihypertensive is critically determined by renal function and volume status. Amlodipine, a dihydropyridine calcium channel blocker (CCB), is the safest choice here. The discriminating fact is that amlodipine is not renally eliminated (hepatic metabolism via CYP3A4), requires no dose adjustment in renal failure, and does not worsen renal perfusion. More importantly, CCBs cause afferent arteriolar vasodilation (unlike ACE inhibitors which preferentially dilate efferent arterioles), maintaining glomerular filtration pressure even in compromised kidneys. In acute kidney injury or CKD with oliguria, amlodipine preserves renal blood flow while lowering BP. The clinical presentation—oliguria with edema—suggests volume overload or acute kidney injury; amlodipine's lack of natriuretic effect is acceptable here since diuretics would be contraindicated in oliguria. Per KD Tripathi and Indian nephrology guidelines, CCBs are preferred in renal insufficiency when ACE-I/ARBs are contraindicated or when volume status is uncertain. The headache and hypertension (160/90) are consistent with hypertensive emergency in CKD, where amlodipine provides rapid, predictable BP reduction without worsening renal function.
Why the other options are wrong
B. Prazosin — Prazosin (α1-blocker) causes reflex tachycardia and fluid retention due to sympathetic counter-regulation, worsening the existing pedal edema and volume overload. In oliguria with edema, prazosin is contraindicated because it triggers sodium and water reabsorption, exacerbating renal insufficiency. Additionally, prazosin's unpredictable absorption and first-dose syncope risk make it unsuitable in acute hypertensive states with renal compromise. C. Chlorthalidone — Thiazide diuretics like chlorthalidone are absolutely contraindicated in oliguria and renal insufficiency (GFR <30 mL/min). They worsen volume depletion, precipitate acute kidney injury, and cause electrolyte disturbances (hypokalemia, hyponatremia). In a patient already presenting with very low urine output, a diuretic would further compromise renal perfusion and is a classic NBE trap for students who reflexively choose diuretics for edema. D. Aliskiren — Aliskiren (direct renin inhibitor) is contraindicated in renal insufficiency because it causes preferential efferent arteriolar vasodilation (like ACE-I/ARBs), reducing glomerular filtration pressure and worsening renal function. Additionally, aliskiren is renally eliminated and accumulates in CKD, increasing hyperkalemia risk. In oliguria, aliskiren accelerates decline in GFR and is not recommended per Indian nephrology guidelines.
High-Yield Facts
- Amlodipine in renal insufficiency: hepatically metabolized, no renal excretion, no dose adjustment needed, maintains GFR via afferent vasodilation.
- Dihydropyridine CCBs (amlodipine, nifedipine) are first-line in CKD with hypertension; non-dihydropyridines (verapamil, diltiazem) are avoided due to negative inotropic effects.
- Thiazide diuretics contraindicated when GFR <30 mL/min or in oliguria; loop diuretics only if volume overload with preserved urine output.
- ACE-I/ARB/aliskiren preferentially dilate efferent arterioles → reduce GFR in renal insufficiency; use only if proteinuria present and GFR >30 mL/min.
- Oliguria + edema = volume overload or acute kidney injury; avoid natriuretics and renin-angiotensin system inhibitors; use vasodilators (CCB, hydralazine).
Mnemonics
RENAL FAIL DRUGS (what to AVOID) Renin inhibitors (aliskiren), EACE-I/ARB, Non-dihydropyridine CCB (verapamil), Aldosterone antagonists (spironolactone), Loop/Thiazide diuretics (in oliguria). Use DHPs (amlodipine, nifedipine) instead. CCB SITE OF ACTION (why amlodipine works) Amlodipine = Afferent (dilates afferent arteriole → maintains GFR). ACE-I = Efferent (dilates efferent → drops GFR). In renal failure, choose afferent dilators.
NBE Trap
NBE pairs renal insufficiency with edema to lure students into choosing diuretics (chlorthalidone), forgetting that oliguria is a contraindication for natriuretics. The trap exploits the reflex "edema = diuretic" without checking urine output first.
Clinical Pearl
In Indian tertiary care, oliguria with hypertension in CKD is managed with amlodipine as first-line; ACE-I is added only after urine output recovers and proteinuria is confirmed. This two-step approach prevents acute kidney injury progression and is standard in RNTCP-affiliated nephrology units.
_Reference: KD Tripathi Ch. 12 (Antihypertensives); Harrison Ch. 280 (Chronic Kidney Disease); Robbins Ch. 20 (Kidney pathology)_